These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6595680)

  • 21. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sumatriptan-induced growth hormone release in patients with major depression, mania, and normal controls.
    Yatham LN; Zis AP; Lam RW; Tam E; Shiah IS
    Neuropsychopharmacology; 1997 Oct; 17(4):258-63. PubMed ID: 9326750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion.
    Goodnick PJ; Meltzer HY
    J Clin Psychopharmacol; 1983 Aug; 3(4):239-43. PubMed ID: 6411776
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion.
    Nair NP; Lal S; Iskandar HI; Etienne P; Wood PL; Guyda H
    Brain Res Bull; 1982 Jun; 8(6):587-91. PubMed ID: 7139355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.
    Balldin J; Granérus AK; Lindstedt G; Modigh K; Wålinder J
    Psychopharmacology (Berl); 1982; 76(4):371-6. PubMed ID: 6812112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine evaluation of catecholaminergic neurotransmission in mania.
    Ansseau M; von Frenckell R; Cerfontaine JL; Papart P; Franck G; Timsit-Berthier M; Geenen V; Legros JJ
    Psychiatry Res; 1987 Nov; 22(3):193-206. PubMed ID: 2829258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin function and depression: neuroendocrine and mood responses to intravenous L-tryptophan in depressed patients and healthy comparison subjects.
    Price LH; Charney DS; Delgado PL; Heninger GR
    Am J Psychiatry; 1991 Nov; 148(11):1518-25. PubMed ID: 1928466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dopamine system challenge in affective disorders: a review of behavioral and neuroendocrine responses.
    Insel TR; Siever LJ
    J Clin Psychopharmacol; 1981 Jul; 1(4):207-13. PubMed ID: 7028802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine effects of domperidone: a peripheral dopamine blocking agent.
    Brown GM; Verhaegan H; Van Wimersma Greidanus TB; Brugmans J
    Clin Endocrinol (Oxf); 1981 Sep; 15(3):275-82. PubMed ID: 7307290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
    Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
    Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased sensitivity of dopamine receptors and recurrence of affective psychosis after childbirth.
    Wieck A; Kumar R; Hirst AD; Marks MN; Campbell IC; Checkley SA
    BMJ; 1991 Sep; 303(6803):613-6. PubMed ID: 1805821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine autoreceptor stimulation: clinical significance.
    Meltzer HY
    Pharmacol Biochem Behav; 1982; 17 Suppl 1():1-10. PubMed ID: 6223322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F; Bellodi L; Perna G; Arancio C; Bertani A
    Biol Psychiatry; 1997 Nov; 42(10):889-97. PubMed ID: 9359974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response.
    Post RM; Gerner RH; Carman JS; Gillin JC; Jimerson DC; Goodwin FK; Bunney WE
    Arch Gen Psychiatry; 1978 May; 35(5):609-15. PubMed ID: 215097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients.
    Golden RN; Hsiao JK; Lane E; Ekstrom D; Rogers S; Hicks R; Potter WZ
    Psychiatry Res; 1990 Jan; 31(1):39-47. PubMed ID: 2156276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM
    Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of dopamine, apomorphine and piribedil on the mesenterial blood flow of the cat.
    György L; Dóda M
    Arch Int Pharmacodyn Ther; 1985 May; 275(1):22-32. PubMed ID: 4026462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic sensitivity and cocaine abuse: response to apomorphine.
    Hollander E; Nunes E; DeCaria CM; Quitkin FM; Cooper T; Wager S; Klein DF
    Psychiatry Res; 1990 Aug; 33(2):161-9. PubMed ID: 2243893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormones, dopamine receptors and schizophrenia.
    Meltzer HY; Busch D; Fang VS
    Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
    Kolakowska T; Gelder M; Fraser S
    Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.